{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066382","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.734258+00:00","generated_at":"2026-05-22T05:10:07.526463+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cullinan Q1 net loss $48.5M; CLN-978 gains EMA approval for RA, expands into Sjögren's","bullets":["Net loss of $48.5M in Q1 2025 vs $37.1M in Q1 2024; R&D expenses rose to $41.5M.","Cash and investments $567.4M as of March 31, 2025; runway into 2028 reaffirmed.","EMA approved Phase 1 study of CLN-978 in active, difficult-to-treat rheumatoid arthritis; to start Q2 2025.","CLN-978 Phase 1 in Sjögren's disease to initiate in U.S. in Q2 2025; SLE data expected Q4 2025.","CLN-619 discontinued in gynecological cancers; zipalertinib REZILIENT1 results at ASCO June 1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066382","json":"https://secwatch.observer/filing/0000950170-25-066382.json","markdown":"https://secwatch.observer/filing/0000950170-25-066382.md","text":"https://secwatch.observer/filing/0000950170-25-066382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017025066382/0000950170-25-066382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017025066382/cgem-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:10:07.526463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}